Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG (TiCAB)
A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared With Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation TiCAB- Ticagrelor in CABG
Sponsor: AstraZeneca
Terminated
DSMB Interim Analyses
Other terminated trials from AstraZeneca
Other Acute Coronary Syndrome trials with similar outcome
A PHASE3 clinical study on Acute Coronary Syndrome and Coronary Artery Disease, this trial is terminated or withdrawn. The trial is conducted by AstraZeneca and has accumulated 7 data snapshots since 2013. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Sep 2018 — Jan 2021 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
▶ Show 2 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Deutsches Herzzentrum Muenchen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Bad Bevensen, Germany , Bad Nauheim, Germany , Berlin, Germany , Bern, Switzerland , Bernau bei Berlin, Germany , Bremen, Germany , Cottbus, Germany , Düsseldorf, Germany , Erlangen, Germany and 17 more locations